Wednesday, September 30, 2015
The U.S. Patent and Trademark Office has invalidated a patent held by drugmaker Novartis AG related to its multiple sclerosis drug Gilenya on grounds of obviousness.
Michael Levy of Kenyon & Kenyon, who advised generic drug maker Torrent Pharmaceuticals Ltd, the lead plaintiff in the case, said the decision issued last Thursday was noteworthy because it marked one of the first uses by drug companies of the USPTO's inter partes review process, which was established by the America Invents Act of 2011.
reuters.com
